Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (?4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml)

Basit Öğe Kaydı
dc.contributor.authorÇalışkan, Selahattin
dc.date.accessioned2019-05-13T08:58:35Z
dc.date.available2019-05-13T08:58:35Z
dc.date.issued2017
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractAim of Study: Serum prostate-specific antigen (PSA) is a useful tumor biomarker for prostate cancer (PCa) diagnosis. In this study, I aimed to compare the free/total PSA (fPSA%) with PSA alone for their usefulness in diagnosis for PCa. Methods: The patients who underwent prostate biopsy between January 2010 and January 2015 were evaluated retrospectively. Data were expressed as a mean + standard error and P < 0.05 as considered with statistical significance (Med Calc 14.12-2014). The receiver operating characteristic curves were calculated to study the sensitivity and specificity of fPSA and PSA and compared to each other in different PSA levels. Results: There were 1055 patients in the study. The mean age of the patients was 64.2 + 7.5 and 66.3 + 6.4 years in Groups 1 and 2. The mean PSA and free/total PSA of the patients was 2.79 + 1 ng/ml, 0.2 + 0.08 and 6.49 + 1.59 ng/ml and 0.19 + 0.09 in Groups 1 and 2, respectively. I found the optimal cutoff for fPSA% was ?18 and ?14 in Groups 1 and 2 with a sensitivity of 62-45% and specificity of 58-79%. There was a statistical significant difference for fPSA when comparing the area under curve in the PSA level of 4.01-10 ng/ml (P = 0.0009). Conclusion: In this study, serum fPSA% has advantages for diagnosis of PCa when comparing PSA alone in different levels of PSA. These advantages are significant in PSA level of 4.01-10 ng/ml. © 2017 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow.
dc.identifier.citationÇalışkan, S. (2017). Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (?4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01–10.0 ng/ml). Journal of Cancer Research and Therapeutics, 13(2), 279-283.
dc.identifier.doi10.4103/0973-1482.183177
dc.identifier.endpage283en_US
dc.identifier.issn0973-1482
dc.identifier.issue2en_US
dc.identifier.scopusqualityQ3
dc.identifier.startpage279en_US
dc.identifier.urihttps://doi.org/10.4103/0973-1482.183177
dc.identifier.urihttps://hdl.handle.net/11491/1162
dc.identifier.volume13en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWolters Kluwer - Medknow
dc.relation.ispartofJournal of Cancer Research and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0/*
dc.subjectDiagnosisen_US
dc.subjectFree/Total Prostate-Specific Antigenen_US
dc.subjectProstate Canceren_US
dc.subjectSensitivityen_US
dc.subjectSpecificityen_US
dc.titleDiagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (?4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml)
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
caliskanselahattin.pdf
Boyut:
656.63 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu